Evidence map›Paper›PMID 39754000›Full record

ArticleDrug delivery and translational research2025

Construction of folic acid modified fluoro-liposomes for oral delivery of erastin to achieve targeted anti-tumor therapy.

Min Hong, Xiaoyan Liu, Qinghong Ji, Mengyao Ou, Qiaoli Yue, Shuang Cheng

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Min HongSchool of Chemistry and Chemical Engineering, Liaocheng University, Liaocheng, 252059, China. hongmin@lcu.edu.cn.ORCID 0000-0001-8406-0323
Xiaoyan LiuSchool of Chemistry and Chemical Engineering, Liaocheng University, Liaocheng, 252059, China.
Qinghong JiSchool of Chemistry and Chemical Engineering, Liaocheng University, Liaocheng, 252059, China.
Mengyao OuSchool of Chemistry and Chemical Engineering, Liaocheng University, Liaocheng, 252059, China.
Qiaoli YueSchool of Chemistry and Chemical Engineering, Liaocheng University, Liaocheng, 252059, China.
Shuang ChengSchool of Agricultural Science and Engineering, Liaocheng University, Liaocheng, 252059, China.

Funding

Shandong Provincial Natural Science Foundations ZR2015BM024
6 · The paper itself

Abstract

Erastin, as an effective ferroptosis inducer, has received extensive attention in anti-tumor research. To develop an oral nanocarrier for high efficient loading hydrophobic erastin, here we prepared a fluoro-liposome (FA-3 F-LS) by the self-assembly of the folic acid modified fluorinated amphiphiles-FA-3 F conjugates. The hydrophobic component of three perfluorooctyl chains endows the FA-3 F-LSs with high stability to resist the harsh gastrointestinal tract condition. Folic acids conjugated on the surface of FA-3 F-LSs ensure the better tumor targeting and higher oral bioavailability (32.1%) of erastin-loaded FA-3 F-LSs (erastin@FA-3 F-LSs) than free erastin (8.98%). As targeted anti-tumor nanomedicines, erastin@FA-3 F-LSs effectively inhibited the tumor cell proliferation in vitro by inducing ferroptosis through enhancing the glutathione (GSH) depletion, lipid peroxidation and generation of reactive oxygen species. In vivo studies demonstrated that FA-3 F-LSs displayed excellent application potential as a tumor-targeted oral drug delivery nanocarrier to depress the tumor growth with the loaded chemotherapeutic agents.

Indexed as

Antineoplastic AgentsFolic AcidPiperazinesAdministration, OralAnimalsBiological AvailabilityCell Line, TumorCell ProliferationDrug Delivery SystemsFerroptosisGlutathioneHumansLiposomesMiceMice, Inbred BALB CMice, NudeAntineoplastic AgentserastinFolic AcidGlutathioneLiposomesPiperazinesReactive Oxygen SpeciesErastinFerroptosisFluorinated amphiphileFluoro-liposomeOral deliveryTargeted anti-tumor therapy

Identifiers

PMID39754000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.